To secure reimbursement in Italy, pharmaceutical companies will have to demonstrate that their medicines offer additional therapeutic value over treatments already on the market, according to a draft decree updating pricing and reimbursement regulations.
The draft decree formally shifts the focus of reimbursement decision-making from cost-effectiveness to additional therapeutic value, according to Roberto Cursano...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?